Cross-neutralizing Activity Against Divergent Human Immunodeficiency Virus Type 1 Isolates Induced by the Gp41 Sequence ELDKWAS

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1994 Jun 1

PMID 7514684

Citations 136

Authors

T Muster

R Guinea

A Trkola

M Purtscher

A Klima

F Steindl

P Palese

H Katinger

Affiliations

Soon will be listed here.

Abstract

Previously we identified the highly conserved amino acids Glu-Leu-Asp-Lys-Trp-Ala (ELDKWA) on the ecto-domain of gp41 as the epitope of a neutralizing monoclonal antibody (2F5) directed against human immunodeficiency virus type 1. In the present study, the sequence defining the epitope was introduced into the loop of antigenic site B of the influenza virus hemagglutinin. The resulting chimeric virus was able to elicit ELDKWA-specific immunoglobulins G and A in antisera of mice. Moreover, the distantly related human immunodeficiency virus type 1 isolates MN, RF, and IIIB were neutralized by these antisera. These data suggest that this conserved B-cell epitope is a promising candidate for inclusion in a vaccine against AIDS. The results also show that influenza virus can be used to effectively present the antigenic structure of this B-cell epitope.

Citing Articles

Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site.

Banach B, Pletnev S, Olia A, Xu K, Zhang B, Rawi R Nat Commun. 2023; 14(1):7593.

PMID: 37989731 PMC: 10663459. DOI: 10.1038/s41467-023-42098-5.

Identification of Anti-gp41 Monoclonal Antibodies That Effectively Target Cytotoxic Immunoconjugates to Cells Infected with Human Immunodeficiency Virus, Type 1.

Klug G, Cole F, Hicar M, Watt C, Peters T, Pincus S Vaccines (Basel). 2023; 11(4).

PMID: 37112741 PMC: 10144985. DOI: 10.3390/vaccines11040829.

Adjuvants influence the maturation of VRC01-like antibodies during immunization.

Knudsen M, Agrawal P, MacCamy A, Parks K, Gray M, Takushi B iScience. 2022; 25(11):105473.

PMID: 36405776 PMC: 9667313. DOI: 10.1016/j.isci.2022.105473.

Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis.

Phelps M, Balazs A Front Immunol. 2021; 12:734304.

PMID: 34603314 PMC: 8479175. DOI: 10.3389/fimmu.2021.734304.

Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.

Wang J, Shu T, Deng W, Zheng Y, Liao M, Ye X J Virol. 2021; 95(12).

PMID: 33789991 PMC: 8315921. DOI: 10.1128/JVI.00059-21.

References

SCHULMAN J, Palese P . Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells. J Virol. 1977; 24(1):170-6. PMC: 515920. DOI: 10.1128/JVI.24.1.170-176.1977. View

Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M . Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses. 1994; 10(4):359-69. DOI: 10.1089/aid.1994.10.359. View

Robert-Guroff M, Reitz Jr M, Robey W, Gallo R . In vitro generation of an HTLV-III variant by neutralizing antibody. J Immunol. 1986; 137(10):3306-9. View

Weiss R, Clapham P, Weber J, Dalgleish A, Lasky L, BERMAN P . Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 1986; 324(6097):572-5. DOI: 10.1038/324572a0. View

Matthews T, Langlois A, Robey W, Chang N, Gallo R, Fischinger P . Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A. 1986; 83(24):9709-13. PMC: 387210. DOI: 10.1073/pnas.83.24.9709. View

Palker T, Clark M, Langlois A, Matthews T, Weinhold K, Randall R . Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A. 1988; 85(6):1932-6. PMC: 279895. DOI: 10.1073/pnas.85.6.1932. View

Goudsmit J, Debouck C, Meloen R, Smit L, Bakker M, Asher D . Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A. 1988; 85(12):4478-82. PMC: 280453. DOI: 10.1073/pnas.85.12.4478. View

Reitz Jr M, Wilson C, Naugle C, Gallo R, Robert-Guroff M . Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell. 1988; 54(1):57-63. DOI: 10.1016/0092-8674(88)90179-1. View

Looney D, Fisher A, Putney S, Rusche J, Redfield R, Burke D . Type-restricted neutralization of molecular clones of human immunodeficiency virus. Science. 1988; 241(4863):357-9. DOI: 10.1126/science.3388046. View

10.

Evans D, McKeating J, Meredith J, Burke K, Katrak K, John A . An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature. 1989; 339(6223):385-8, 340. DOI: 10.1038/339385a0. View

11.

McKeating J, Gow J, Goudsmit J, Pearl L, Mulder C, Weiss R . Characterization of HIV-1 neutralization escape mutants. AIDS. 1989; 3(12):777-84. DOI: 10.1097/00002030-198912000-00001. View

12.

Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, NYSTROM G . Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS. 1990; 4(2):107-12. DOI: 10.1097/00002030-199002000-00002. View

13.

ENAMI M, Luytjes W, Krystal M, Palese P . Introduction of site-specific mutations into the genome of influenza virus. Proc Natl Acad Sci U S A. 1990; 87(10):3802-5. PMC: 53991. DOI: 10.1073/pnas.87.10.3802. View

14.

Nara P, Smit L, Dunlop N, HATCH W, Merges M, Waters D . Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol. 1990; 64(8):3779-91. PMC: 249673. DOI: 10.1128/JVI.64.8.3779-3791.1990. View

15.

Javaherian K, Langlois A, LaRosa G, Profy A, Bolognesi D, Herlihy W . Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science. 1990; 250(4987):1590-3. DOI: 10.1126/science.1703322. View

16.

Muster T, Subbarao E, ENAMI M, Murphy B, Palese P . An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice. Proc Natl Acad Sci U S A. 1991; 88(12):5177-81. PMC: 51835. DOI: 10.1073/pnas.88.12.5177. View

17.

Wang C, Looney D, Li M, Walfield A, Ye J, Hosein B . Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science. 1991; 254(5029):285-8. DOI: 10.1126/science.254.5029.285. View

18.

BERMAN P, Matthews T, Riddle L, Champe M, Hobbs M, NAKAMURA G . Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J Virol. 1992; 66(7):4464-9. PMC: 241255. DOI: 10.1128/JVI.66.7.4464-4469.1992. View

19.

Ahlers J, Pendleton C, Dunlop N, Minassian A, Nara P, Berzofsky J . Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. J Immunol. 1993; 150(12):5647-65. View

20.

Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G . A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993; 67(11):6642-7. PMC: 238102. DOI: 10.1128/JVI.67.11.6642-6647.1993. View